RecruitingNot Applicable

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

United States25 participantsStarted 2025-10-16

Plain-language summary

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 * Enrollment in main CS-reducer HFPEF study IRB# 25-002292 Exclusion Criteria: * Metal implants that are not suitable for MRI * Inability or unwillingness of individual to give written informed consent.

What they're measuring

Change in endocardial:epicardial perfusion ratio

Timeframe: Baseline, 6 Months

Trial details

NCT IDNCT07093528

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-08

Contact for this trial

Diana Albers

507-255-6884 albers.diana2@mayo.edu

View on ClinicalTrials.gov More Heart Failure With Preserved Ejection Fraction trials